How much is the personalized cancer vaccines market worth, and how is it expected to expand?
The personalized cancer vaccines market size has grown strongly in recent years. It will grow from $242.29 billion in 2024 to $259.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to advancements in genomic research, development of targeted therapies, increased understanding of tumor immunology, progress in vaccine technology and growing clinical trial data supporting efficacy.
The personalized cancer vaccines market size is expected to see strong growth in the next few years. It will grow to $336.03 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to advancements in precision medicine, increasing funding for cancer research, rising prevalence of cancer cases, improvements in genetic sequencing technologies and growing interest in personalized treatment options. Major trends in the forecast period include the integration of artificial intelligence in vaccine design, advances in multi-antigen and neoantigen-based vaccines, increased use of liquid biopsies for tumor monitoring, expansion of combination therapies, and greater focus on personalized treatment regimens.
Get Your Free Sample of The Global Personalized Cancer Vaccines Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19136&type=smp
Which industry factors have accelerated the personalized cancer vaccines market’s expansion?
The increasing prevalence of cancer is expected to propel the growth of the personalized cancer vaccine market going forward. Cancer refers to a collection of diseases marked by abnormal cell growth that can spread to other parts of the body. The increasing prevalence of cancer is due to aging populations, lifestyle changes, environmental pollutants, genetic predispositions, and improved diagnostic techniques. Personalized cancer vaccines help prevent the increasing prevalence of cancer by targeting specific tumor antigens unique to each patient, enhancing the immune system’s ability to recognize and destroy cancer cells. For instance, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in Australia the number of cancer cases diagnosed increased from 160,570 in 2022 to 164,694 in 2023, reflecting a notable rise over the year. Therefore, the increasing prevalence of cancer is driving the growth of the personalized cancer vaccine market.
What are the primary segments of the personalized cancer vaccines market?
The personalized cancer vaccinesmarket covered in this report is segmented –
1) By Treatment Type: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
2) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Cervical Cancer, Glioblastoma
3) By Mechanism Of Action: Tumor Associated Antigens (TAAs), Tumor Specific Antigens (TSAs), Somatic Mutations In Cancer Pharmacogenomics, Pharmacogenomics Towards Genomic Polymorphism, Other Mechanisms Of Action
4) By Route Of Administration: Injectables, Other Routes Of Administration
5) By End Use: Hospitals, Clinic, Other End Users
Subsegments:
1) By Preventive Cancer Vaccines: HPV Vaccines, Hepatitis B Vaccines, Combination Vaccines
2) By Therapeutic Cancer Vaccines: Dendritic Cell Vaccines, Peptide-Based Vaccines, DNA Vaccines, RNA Vaccines, Whole Cell Vaccines
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/personalized-cancer-vaccines-global-market-report
Which firms are leading the personalized cancer vaccines market?
Major companies operating in the personalized cancer vaccines market are Merck & Co Inc., GlaxoSmithKline Plc, NEC Corporation, Moderna Inc., Catalent Inc., UCLA Health, Genetech Inc., NHS England, CureVac AG, Personalis Inc., Achilles Therapeutics Plc, Healio, Moffitt Corporation, BioPharma APAC, Celebrity Angels, EpiVax Therapeutics Inc., Evaxion Biotech AS, Geneos Therapeutics Inc., IFL Sciense, ISA Pharmaceuticals BV, Oxford Global, Kintara Therapeutics, VAXIMM Gmbh
Which market trends are set to define the future of the personalized cancer vaccines market?
Major companies operating in the personalized cancer vaccine market are focused on developing advanced therapeutic solutions, such as personalized immunotherapy, to enhance precision in treating specific cancer mutations. Personalized immunotherapy solutions are customized treatments designed to use a patient’s unique genetic and tumor characteristics to improve immune system responses against cancer. For instance, in August 2024, UCLA Health, a US-based healthcare organization, launched a first-of-its-kind clinical trial to evaluate the safety and effectiveness of a cancer vaccine. The vaccine developed at UCLA leverages a personalized immunotherapy approach that targets the H3 G34 mutation in diffuse hemispheric gliomas, a highly aggressive brain tumor often found in adolescents and young adults. It uniquely utilizes dendritic cells to activate the immune system against the specific RNA disruptions caused by this mutation. The approach, which has shown promise in treating other cancers, aims to improve outcomes for patients who typically face limited treatment options and short survival times.
Which geographic trends are shaping the personalized cancer vaccines market, and which region has the highest market share?
North America was the largest region in the personalized cancer vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Personalized Cancer Vaccines Market Report 2025 Offer?
The personalized cancer vaccines market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Personalized cancer vaccines refer to treatments tailored to an individual’s unique tumor profile, aiming to stimulate their immune system to target and destroy cancer cells. They improve the body’s ability to recognize and fight specific cancer types, potentially enhancing treatment efficacy and reducing recurrence.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19136
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
